US 11,690,856 B2
Compounds for treating CMV related diseases
Pierre Szepetowski, Marseilles (FR); Robin Cloarec, Marseilles (FR); Sylvian Bauer, Marseilles (FR); and Nadine Bruneau, Marseilles (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); and UNIVERSITE D'AIX MARSEILLE, Marseilles (FR)
Appl. No. 16/758,292
Filed by INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); and UNIVERSITE D'AIX MARSEILLE, Marseilles (FR)
PCT Filed Oct. 22, 2018, PCT No. PCT/EP2018/078889
§ 371(c)(1), (2) Date Apr. 22, 2020,
PCT Pub. No. WO2019/081428, PCT Pub. Date May 2, 2019.
Claims priority of application No. 17306455 (EP), filed on Oct. 23, 2017.
Prior Publication US 2020/0338095 A1, Oct. 29, 2020
Int. Cl. A61K 31/65 (2006.01); A61P 25/28 (2006.01); A61K 31/663 (2006.01)
CPC A61K 31/65 (2013.01) [A61K 31/663 (2013.01); A61P 25/28 (2018.01)] 12 Claims
 
1. A method of treating cytomegalovirus (CMV) related diseases in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound that modifies microglia,
wherein the compound is clodronate or a tetracycline family compound, and
wherein the CMV related disease is a disorder associated with perinatal or congenital CMV infection selected from the group consisting of microcephaly, polymicrogyria, hearing loss, cerebral palsy, epileptic seizures and intellectual disability.